Generalized atrophic benign epidermolysis bullosa.

Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants. J Med Genet (2006) 1.29

Compound heterozygosity for a dominant glycine substitution and a recessive internal duplication mutation in the type XVII collagen gene results in junctional epidermolysis bullosa and abnormal dentition. Am J Pathol (1996) 1.19

Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation. J Clin Invest (1999) 1.17

Inherited epidermolysis bullosa. Orphanet J Rare Dis (2010) 1.16

180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. J Clin Invest (1995) 1.16

Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol (2013) 1.02

Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am J Hum Genet (2005) 1.02

Three novel homozygous point mutations and a new polymorphism in the COL17A1 gene: relation to biological and clinical phenotypes of junctional epidermolysis bullosa. Am J Hum Genet (1997) 0.98

Prenatal diagnosis of junctional epidermolysis bullosa associated with pyloric atresia. J Med Genet (1990) 0.97

Cloning of the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized atrophic benign epidermolysis bullosa. Am J Hum Genet (1997) 0.93

Epidermolysis bullosa with pyloric atresia: novel mutations in the beta4 integrin gene (ITGB4). Am J Pathol (1998) 0.90

Collagen XVII (BP180) modulates keratinocyte expression of the proinflammatory chemokine, IL-8. Exp Dermatol (2012) 0.89

Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin Dermatol (2013) 0.87

Type XVII collagen (BP180) can function as a cell-matrix adhesion molecule via binding to laminin 332. Matrix Biol (2010) 0.83

Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: implications for gene therapy. J Invest Dermatol (2008) 0.76

Non-lethal junctional epidermolysis bullosa in two adult sisters. J R Soc Med (1985) 0.75

Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87

Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J Virol (2000) 3.77

Epidermal Langerhans cells--a target for HTLV-III/LAV infection. J Invest Dermatol (1987) 3.41

Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol (1995) 3.34

Epidermal Langerhans cells bear Fc and C3 receptors. Nature (1977) 3.21

Diagnostic accuracy of dermoscopy. Lancet Oncol (2002) 3.14

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med (1987) 3.13

Frequency and characteristics of enlarging common melanocytic nevi. Arch Dermatol (2000) 2.75

Impact of landscape management on the genetic structure of red squirrel populations. Science (2001) 2.34

Ultraviolet light depletes surface markers of Langerhans cells. J Invest Dermatol (1981) 2.28

Expression of Thy-1 antigen by murine epidermal cells. J Invest Dermatol (1983) 2.20

Phototesting and dosimetry for photochemotherapy. Br J Dermatol (1977) 2.17

Revised classification system for inherited epidermolysis bullosa: Report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol (2000) 1.97

In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol (1987) 1.90

Ecstasy pill testing: harm minimization gone too far? Addiction (2001) 1.85

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol (1998) 1.82

The fine structure of the Langerhans cell granule. J Cell Biol (1967) 1.79

Evidence of HLA-DR antigen biosynthesis by human keratinocytes in disease. J Exp Med (1984) 1.75

Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 1.68

The langerhans cell. Curr Probl Dermatol (1972) 1.67

Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol (1988) 1.62

Methadone maintenance and tuberculosis treatment. BMJ (1996) 1.61

Antigen presentation by murine epidermal langerhans cells and its alteration by ultraviolet B light. J Immunol (1981) 1.60

Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol (1997) 1.60

Cyclosporin A suppresses ICAM-1 expression by papillary endothelium in healing psoriatic plaques. J Invest Dermatol (1991) 1.60

Human epidermal T cells predominantly belong to the lineage expressing alpha/beta T cell receptor. J Exp Med (1990) 1.57

Ultrastructural localization of immunoglobulins in bullous pemphigoid skin. Employment of a new peroxidase-antiperoxidase multistep method. J Invest Dermatol (1975) 1.57

Uptake, intracellular transport and degradation of exogenous protein by Langerhans cells. An electron microscopic-cytochemical study using peroxidase as tracer substance. J Invest Dermatol (1970) 1.56

Permeability of the epidermis and the phagocytic activity of keratinocytes. Ultrastructural studies with thorotrast as a marker. J Ultrastruct Res (1971) 1.55

[Odland bodies (Membrane coating granules, keratinosomes) as epidermal lysosomes. An electron microscopic-cytochemical contribution on the cornification process of the skin]. Arch Klin Exp Dermatol (1967) 1.51

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med (1998) 1.50

Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Eur J Cancer (1998) 1.48

Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem (1998) 1.47

Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol (1990) 1.47

Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ. J Invest Dermatol (1991) 1.43

Skin tumors in the European PUVA Study. Eight-year follow-up of 1,643 patients treated with PUVA for psoriasis. J Am Acad Dermatol (1987) 1.42

Statistical evaluation of epiluminescence microscopy criteria for melanocytic pigmented skin lesions. J Am Acad Dermatol (1993) 1.41

Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice. J Invest Dermatol (1998) 1.41

Substance misuse among health care workers: national survey of occupational physicians. Occup Med (Lond) (2012) 1.40

Life history of cutaneous vascular lesions in Sneddon's syndrome. Hum Pathol (1992) 1.39

[Photochemotherapy of psoriasis: clinical experiences with 152 patients (author's transl)]. Dtsch Med Wochenschr (1975) 1.38

Molecular analysis of plant migration and refugia in the Arctic. Science (2000) 1.37

Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med (1999) 1.35

Quantitative studies on the Langerhans cell population of guinea pig epidermis. J Invest Dermatol (1967) 1.31

[The Langerhans cells. Results of newer experimental studies. I]. Arch Klin Exp Dermatol (1967) 1.30

Langerhans cells as stimulator cells in the murine primary epidermal cell-lymphocyte reaction: alteration by UV-B irradiation. J Invest Dermatol (1982) 1.30

P45, an extracellular 45 kDa protein of Listeria monocytogenes with similarity to protein p60 and exhibiting peptidoglycan lytic activity. Arch Microbiol (2000) 1.27

Langerhans' cells are an actual site of HIV-1 replication. Intervirology (1988) 1.27

Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J Immunol (1997) 1.25

An electron microscopic study on the extraneous coat of keratinocytes and the intercellular space of the epidermis. J Invest Dermatol (1968) 1.24

Ultrastructural localization of nucleoside triphosphatase in Langerhans cells. J Invest Dermatol (1967) 1.22

A localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma. Br J Dermatol (2001) 1.21

Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21

Cannabis use in patients with multiple sclerosis. Mult Scler (2006) 1.21

Ultrastructural localization of pemphigus autoantibodies within e epidermis. Nature (1971) 1.21

Mechanism of UV-B-induced impairment of the antigen-presenting capacity of murine epidermal cells. J Immunol (1983) 1.20

Induction of UV light tolerance by PUVA in patients with polymorphous light eruption. Br J Dermatol (1978) 1.20

In vivo epiluminescence microscopy of pigmented skin lesions. II. Diagnosis of small pigmented skin lesions and early detection of malignant melanoma. J Am Acad Dermatol (1987) 1.19

Immunofluorescence mapping of antigenic determinants within the dermal-epidermal junction in the mechanobullous diseases. J Invest Dermatol (1981) 1.17

Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol (2000) 1.17

[The permeability of the intercellular space of the epidermis for low molecular weight protein. Electron microscopic cytochemical studies with peroxidase as a tracer substance]. Arch Klin Exp Dermatol (1969) 1.17

Photoprotective effect of a psoralen-UVA-induced tan. Arch Dermatol Res (1978) 1.17

Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation. J Clin Invest (1999) 1.17

Interleukin 2 receptors on cultured murine epidermal Langerhans cells. J Immunol (1986) 1.16

Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus. J Exp Med (1989) 1.16

Leu-3/T4 expression on epidermal Langerhans cells in normal and diseased skin. J Invest Dermatol (1986) 1.16

[Uptake, intracellular transport, and degradation of exogenous protein by keratinocytes. Electron microscopy and cytochemical study using peroxidase as a tracer substance]. Arch Klin Exp Dermatol (1969) 1.15

MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol (1993) 1.15

Epidermal lysosomes. Electron microscopic-cytochemical studies. Arch Dermatol (1970) 1.15

Generalized eruptive histiocytoma. Enzyme histochemistry and electron microscopy. Arch Dermatol (1967) 1.14

The use of solid-phase radioimmunoassay techniques for serodiagnosis of human plague infection. Bull Pan Am Health Organ (1980) 1.13

Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa. Acta Derm Venereol (2001) 1.12

In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol (1993) 1.11

Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A (1999) 1.10

The disappearance and regeneration of Langerhans cells following epidermal injury. J Invest Dermatol (1968) 1.10

Phagocytosis of latex beads by epidermal keratinocytes in vivo. J Ultrastruct Res (1972) 1.08

Maturational steps of bone marrow-derived dendritic murine epidermal cells. Phenotypic and functional studies on Langerhans cells and Thy-1+ dendritic epidermal cells in the perinatal period. J Immunol (1989) 1.07

The Langerhans cell. J Invest Dermatol (1983) 1.06

Expression of basement membrane zone antigens at the dermo-epibolic junction in organ cultures of human skin. J Invest Dermatol (1980) 1.06

Experimental staphylococcal toxic epidermal necrolysis (TEN) in adult humans and mice. J Lab Clin Med (1974) 1.05

Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro. J Immunol (1996) 1.04

A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res (2001) 1.04

Staphylococcal toxic epidermal necrolysis: pathogenesis and studies on the subcellular site of action of exfoliatin. J Invest Dermatol (1975) 1.04

Sulfone treatment of granuloma annulare. J Am Acad Dermatol (1985) 1.03

[On the autoradiographic labelling of Langerhans cells with H3-thymidine]. Arch Klin Exp Dermatol (1967) 1.03

Intra-epidermal eccrine poroma: a histochemical and enzyme-histochemical study. Cancer (1969) 1.02

Improvement of the diagnostic accuracy in pigmented skin lesions by epiluminescent light microscopy. Anticancer Res (1987) 1.02

A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med (2000) 1.01

Hepatocellar hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation. Lab Invest (1975) 1.01

Urinary neopterin: an early marker of HIV infection. Eur J Clin Microbiol (1987) 1.01

Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol (2001) 1.00

The giant melanosome: a model of deranged melanosome-morphogenesis. J Ultrastruct Res (1974) 0.99

Elevated procaspase levels in human melanoma. Melanoma Res (2001) 0.99

[Systemic nevomatosis: hairy nevus, multiple eruptive nevi and nevus-cell metastasis in lymph nodes]. Hautarzt (1974) 0.99

Necrobiosis lipoidica: treatment with systemic corticosteroids. Br J Dermatol (1992) 0.98

Experimental induction of hepatocellular hyalin (Mallory bodies) in mice by griseofulvin treatment. 1. Light microscopic observation. Lab Invest (1976) 0.98

5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis. Br J Dermatol (1979) 0.98

A homozygous deletion mutation in the gene encoding the 180-kDa bullous pemphigoid antigen (BPAG2) in a family with generalized atrophic benign epidermolysis bullosa. J Invest Dermatol (1996) 0.97

Route of drug use and its implications for drug effect, risk of dependence and health consequences. Drug Alcohol Rev (1998) 0.97